Complement inhibitors are administered as subcutaneous infusions, intravenous infusions or oral capsules.
Here is a list of some well-known complement inhibitors (source: RXList):
- Evacopan
- Eculizumab
- Empaveli
- Enjaymo
- Gohibic
- Pegcetacoplan
- Pozelimab
- Pozelimab-bbfg
- Ravulizumab
- Ravulizumab-cwvz
- Soliris
- Sutimlimab
- Sutimlimab-jome
- Tavneos
- Ultomiris
- Veopoz
- Zilucoplan
We recommend to read the following study for a better understanding of the cell damages that seem to be caused in a large group of Long Covid patients by the complement system: https://www.usz.ch/en/complement-system-causes-cell-damage-in-long-covid/
Anecdotal note: The Complement System seems to return to its normal state after H.E.L.P. Apheresis treatments / Combination Therapy in most patients. Single healing attempts with off-label use of complement system inhibitors are not very common yet and there is little known about the efficiency of the various existing inhibitors in Long Covid.
*Despite emergency use authorisation of certain complement inhibitors for COVID-19, Complement System Treatment will first be available when sufficient clinical evidence is collected for targeted off-label use. One thing to consider is the numerous side-effects of the various complement inhibitors.
Why do we publish this information? We get many enquiries regarding Complement Treatment and want to share what is known so far.
IMPORTANT NOTE: Rituximab despite a very similar sounding name is NOT a complement inhibitor - it is a complement activator and important for B-Cell depletion therapy (which has been mainly researched for multiple sclerosis but is now subject of research in other chronic conditions too)